Figure 2

Anticancer action of ARL-17477 is NOS1-independent. (A) Alignment of NOS1 gene sequences of wild-type and NOS1−/− cell lines derived from U251-MG. (B) Growth curves of wild-type (black) and three NOS1−/− cell lines (red, blue, and green). NOS1−/− cell lines retained the normal growth rates with a doubling time of approximately 1.5 days. (C) Cell viability curves following 3 days of ARL-17477 treatment.